Human Anti-Plague Monoclonal Antibodies Protect Mice from Yersinia pestis in a Bubonic Plague Model
Figure 3
Epitope mapping of the human anti-F1 and anti-V antibodies by peptide binding assay.
A. Each of twenty-seven peptides that covered the full length of the F1-antigen were used to coat an ELISA plate (0.05 ml of a 25 µg/ml solution of each peptide), and binding by the human anti-F1 m252 mAb (0.05 ml of a 10 µg/ml solution) was analyzed. The sample labeled F1 was the full-length antigen used to coat the plate as the positive control (0.05 ml of a 2 µg/ml solution), and the sample labeled Media was the negative control with no primary antibody added. B and C. Each of fifty-two peptides that covered the full length of the V- antigen was used to coat an ELISA plate (0.05 ml of a 25 µg/ml solution), and the human anti-V m253 (B) and m254 (C) mAbs were used (0.05 ml of a 10 µg/ml solution), respectively, to analyze for binding. The sample labeled V was the positive control (0.05 ml of a 2 µg/ml solution), and the sample labeled Media was the negative control without the primary antibody.